Note: The material submitted appears to include text from two different legislative proposals in different jurisdictions. Below are separate, clearly labeled summaries for each bill included in the packet.
1) Massachusetts — H.3119 (House Docket No. 3675)
Title given in docket: An Act relative to taxation of equipment used to provide broadband communication services
Purpose
To exempt from the state sales tax certain machinery, equipment, and replacement parts sold to communications service providers when used to provide broadband communications services.
Key provisions
- Adds a new subsection (aaa) to G.L. c. 64H, §6 (sales tax law) exempting sales of “machinery, equipment, or replacement parts” to communications service providers for use in providing broadband communications services.
- Lists illustrative covered items: wires, cables, fiber, conduits, antennas, poles, switches, routers, amplifiers, power and backup equipment, diagnostic equipment, storage devices, modems, central office/headend equipment (channel cards, frames, cabinets), and successor technologies — plus software, ancillary components, appurtenances and accessories used in whole or in part to provide broadband.
- Defines “broadband communications services” to include telecommunications service, video programming service, internet access service, or any combination.
- Cross-references existing statutory definitions for “telecommunications service” and adopts federal definition for “internet access service” per the Internet Tax Freedom Act.
- Effective date: applies to sales occurring on and after July 1, 2025.
Who is affected
- Primary: communications service providers (ISPs, cable operators, telecoms) purchasing broadband-related equipment.
- Secondary: equipment suppliers and installers (sales may become tax-exempt), state revenue (potential reduction in sales tax collections), and consumers indirectly (possible effect on deployment costs and broadband pricing).
Procedural status (Massachusetts)
- Prefiled Dec 5, 2024; introduced/read first time Jan 14, 2025.
- Referred to committee (multiple entries show Referral to Committee on Medical, Military, Public and Municipal Affairs and later to Revenue — docket shows Revenue committee review on 2025-02-27).
- Sponsor: Rep. Richard M. Haggerty; member Edgerton added as sponsor on 2025-02-12.
- Hearing(s) scheduled/rescheduled for October 2025 per docket entries.
2) South Carolina — Proposed addition of Section 44-43-15 (blood, tissue, organ testing)
(Separate bill text included in packet; jurisdiction: South Carolina)
Purpose
To require testing and labeling of donated blood, blood products, tissues, and organs for the presence of specified contaminants (described in the bill as “high-count spike proteins from long COVID-19” and “products created from gene therapy biologics”), to require patient consent before use of labeled products, impose civil penalties for violations, and provide limited legal immunity for entities complying with the statute.
Key provisions
- Requires testing of whole blood, plasma, blood derivatives, other human tissue, and organs for the specified contaminants before use in transfusion/transplantation.
- Mandates that donated products be sent to a laboratory licensed by the Department of Public Health for testing and that contaminated products be labeled.
- Requires written informed consent from patients before administering labeled contaminated products; patients may decline without penalty (including loss of place on waiting lists).
- Civil penalty: $500 for each patient who receives a product that was not tested as required or received a contaminated product without consenting in writing.
- Provides immunity from arrest, prosecution, civil or administrative penalties (including professional discipline) for entities acting in compliance if patient harm results from the contaminants.
- Defines “gene therapy biologics” broadly to include biological products capable of altering or acting like genes, explicitly including messenger RNA (mRNA).
- Effective date: upon approval by the Governor (state law takes effect on enactment).
Who is affected
- Blood banks, eye banks, organ procurement organizations, hospitals, transplant centers, clinical laboratories (DPH licensing).
- Patients awaiting transfusion/transplantation (consent and potential access implications).
- The state public health and regulatory apparatus (implementation, lab capacity, oversight).
- Possible financial and operational impacts on donation/transplant logistics and costs.
Implementation and practical considerations
- The bill specifies testing and labeling but does not define validated tests, thresholds for “high-count,” or laboratory capacity requirements — these are critical operational details that would affect feasibility, cost, turnaround time, and clinical practice.
- Potential impacts include increased testing costs, delays in distribution of donated products, effects on organ allocation and blood availability, and legal/regulatory implications for providers.
If you want, I can:
- Draft a one-page brief focused on likely fiscal and operational impacts for either bill, or
- Produce suggested questions for the revenue/health committee to probe implementation details (testing standards, fiscal estimates, effect on service deployment or blood supply).
